Steviol glycosides from Stevia rebaudiana Bertoni mitigate lipid metabolism abnormalities in diabetes by modulating selected gene expression – An in vivo study

cris.virtual.author-orcid0000-0002-4731-6243
cris.virtual.author-orcid0000-0002-4399-7459
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcidd951fe7e-3886-48a5-8661-b05d0c844622
cris.virtualsource.author-orcid10fdded3-5140-4fbe-80bb-03575e77544c
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
dc.abstract.enIn diabetes, in parallel to hyperglycaemia, elevated serum lipids are also diagnosed, representing a high-risk factor for coronary heart disease and cardiovascular complications. The objective of this study was to unravel the mechanisms that underlie the potential of steviol glycosides (stevioside or rebaudioside A) administered at two doses (500 or 2500 mg/kg body weight for 5 weeks) to regulate lipid metabolism. In this paper, the expression of selected genes responsible for glucose and lipid metabolism (Glut4, Pparγ, Cebpa, Fasn, Lpl and Egr1) in the peripheral tissues (adipose, liver and muscle tissue) was determined using quantitative real-time PCR method. It was found that the supplementation of steviol glycosides affected the expression of Glut4, Cebpa and Fasn genes, depending on the type of the glycoside and its dose, as well as the type of tissue, whish in part may explain the lipid-regulatory potential of steviol glycosides in hyperglycaemic conditions. Nevertheless, more in-depth studies, including human trials, are needed to confirm these effects, before steviol glycosides can be used in the therapy of type 2 diabetes.
dc.affiliationWydział Nauk o Żywności i Żywieniu
dc.affiliation.instituteKatedra Żywienia Człowieka i Dietetyki
dc.contributor.authorKurek, Jakub Michał
dc.contributor.authorMikołajczyk-Stecyna, Joanna
dc.contributor.authorKrejpcio, Zbigniew
dc.date.access2025-06-06
dc.date.accessioned2025-09-18T11:50:53Z
dc.date.available2025-09-18T11:50:53Z
dc.date.copyright2023-09-05
dc.date.issued2023
dc.description.accesstimeat_publication
dc.description.bibliographyil., bibliogr.
dc.description.financepublication_nocost
dc.description.financecost0,00
dc.description.if6,9
dc.description.numberOctober 2023
dc.description.points140
dc.description.versionfinal_published
dc.description.volume166
dc.identifier.doi10.1016/j.biopha.2023.115424
dc.identifier.eissn1950-6007
dc.identifier.issn0753-3322
dc.identifier.urihttps://sciencerep.up.poznan.pl/handle/item/4924
dc.identifier.weblinkhttps://www.sciencedirect.com/science/article/pii/S0753332223012222
dc.languageen
dc.relation.ispartofBiomedicine and Pharmacotherapy
dc.relation.pagesart. 115424
dc.rightsCC-BY
dc.sciencecloudnosend
dc.share.typeOPEN_JOURNAL
dc.subject.enstevia
dc.subject.ensteviol glycosides
dc.subject.engene expression
dc.subject.enlipid metabolism
dc.subject.endiabetes
dc.subject.enrats
dc.titleSteviol glycosides from Stevia rebaudiana Bertoni mitigate lipid metabolism abnormalities in diabetes by modulating selected gene expression – An in vivo study
dc.typeJournalArticle
dspace.entity.typePublication
oaire.citation.volume166